Administrative Core

行政核心：项目摘要/摘要 哥伦比亚大学乔治·M·奥布莱恩泌尿外科合作研究中心的使命是 促进对良性泌尿生殖系统疾病/疾病的认识。该中心由一个 管理(管理)核心，微生物基因组学生物医学研究核心，以及三项研究 包括临床前和临床研究的项目。我们的重点包括：(1)主持人的交集 基因组与尿微生物组；(2)尿路上皮细胞分化的转录调控 尿路感染后的动态平衡和修复；以及(3)尿液化学和尿路上皮的调节 铁代谢(“铁-血红素机”)是尿路上皮细胞对尿路感染反应的一个组成部分。我们期待着 拟议的研究将为与以下疾病高度相关的疾病的发病机制提供新的见解 良性的泌尿外科，也促进了将基因检测引入泌尿外科的实践，甚至 建议新的治疗方法。我们将研究宿主和入侵细菌之间的相互作用，以及 营养铁在UT感染结果形成中的作用；我们将进行一项新的GWAS分析以 寻找导致LUTD的突变，包括大小便失禁、梗阻和盆底脱垂 将分析下尿路功能障碍(LUTD)患者的尿菌群，并建议 识别可用于治疗良性尿路上皮的尿路上皮细胞类型 与疾病相关的异常。该中心最重要的目标是利用专业知识和 的经验，以扩大我们的研究范围，并帮助指导各种 我们将解决这些问题。我们已经直接整合了P20/U54社区的成员以及 良性泌尿科社区的临床医生和科学家。我们项目的联合调查员包括Indira Mysorekar(P20)是尿路感染和尿路上皮生物学方面的专家，他将与门德尔松博士和Dr。 Barasch，Chad Vezina(威斯康星州U54)和来自良性疾病的合作科学家和临床医生 泌尿外科社区，(Lori Birder，Gerry Apodaca，Doug Strand)。此外，我们还邀请了外部 专家加入我们的工作，例如，血红素生物学家伊克巴尔·哈姆扎(马里兰大学)。我们是 同样高度关注教育和外展：我们的暑期计划已经培训了73名学生 中心已成立，包括本科生、四年级医学生和泌尿科学生 居民。我们为Putonti博士(Loyola大学)和Catherine博士提供了机会池资金 布朗斯坦(哈佛大学)。我们在2019年10月举办了一次研讨会，非常成功 《UTI的问题：泌尿生殖道的微生物群及其免疫防御》汇聚 十几名专家和138名泌尿外科社区成员。

ADMINISTRATIVE CORE: PROJECT SUMMARY/ABSTRACT The mission of the Columbia University George M. O’Brien Urology Cooperative Research Center is to advance the understanding of benign genitourinary diseases/disorders. The Center consists of an Administrative (Admin) Core, a Microbial Genomics Biomedical Research Core, and three Research Projects that include preclinical and clinical studies. Our focus includes: (1) the intersection of the host genome and the urinary microbiome; (2) the transcriptional regulation of urothelial differentiation during homeostasis and repair in response to UTI; and (3) how the regulation of urinary chemistry and urothelial iron metabolism (“iron-heme machine”) is a component of the urothelial response to UTI. We anticipate that the proposed studies will provide new insight into the pathogenesis of disorders of high relevance to benign urology and also facilitate introduction of genetic testing into the practice of Urology and even suggest new treatments. We will examine the interactions between host and invading bacteria, and the role of nutrient iron in shaping the outcome of UT infections; we will undertake a new GWAS analysis to search for mutations that lead to LUTD, including incontinence, obstruction and pelvic floor prolapse, we will analyze the urinary microbiome of patients with lower urinary tract disfunction (LUTD), and we propose to identify pathways that program urothelial cell types that may be used to treat benign urothelial abnormalities associated with disease. The most important goal of this center is to utilize the expertise and experience of the urological community to increase the scope of our studies and to help direct the kinds of questions we will address. We have directly integrated members of the P20/U54 community as well as clinicians and scientists in the benign urological community. Co-investigators on our projects include Indira Mysorekar (P20), an expert in UTI and urothelial biology who will work with Dr. Mendelsohn and Dr. Barasch, Chad Vezina (Wisconsin U54) and collaborating scientists and clinicians from the benign urological community, (Lori Birder, Gerry Apodaca, Doug Strand). In addition, we have invited outside experts to join our work, for example, the heme biologist, Iqbal Hamza (University of Maryland). We are also highly focused on education and outreach: Our summer program has trained 73 students since our center has been established, including undergraduates, fourth year medical students and urology residents. we have provided opportunity pool funds to Dr. Putonti (Loyola University) and Dr. Catherine Brownstein, (Harvard University). We held a Symposium in October of 2019 that was extremely successful "The problem of UTI: The microbiome of the Urogenital Tract and its immune Defense" bringing together a dozen experts with >138 members of the Urological community.